Plaque Psoriasis

This AAD 2024 interview features a discussion with Lebwohl on his team’s new late-breaking data, covering long-term findings on bimekizumab.

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

In late-breaking data from AAD 2024, treatment with the JNJ-2113 targeted oral peptide led to several notable findings regarding patients with moderate-to-severe psoriasis.

In phase 4 data from the IMMpulse study, presented at AAD 2024, comparisons in efficacy were highlighted between risankizumab and apremilast for psoriasis patients eligible for systemic therapy.

Advanced practice providers in dermatology discuss exciting developments in the treatment landscape of plaque psoriasis. Listen to their insights into the often-challenging journey patients go on. The arrival of novel oral systemic treatment options offers opportunities to alleviate the burden of this chronic disease.

Drs Stein Gold, Shahriari and Desai highlight social and cultural stigma of psoriasis in patients with skin of color and its impact on patient’s quality of life.

Expert dermatologists review the presentation of psoriasis in patients with skin of color and the challenges physicians face in diagnosing psoriasis in this patient population.

In the February edition of Dermatology Month in Review, new acne guidelines released by AAD, an FDA decision on nemolizumab, and an interview on potentially the first oral IL-23 inhibitor for psoriasis were among the major stories.

These findings suggest much lower prices can be achieved for medications, with better alignment to the benefits of different biological psoriasis treatments.

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.

This retrospective cohort study suggests the potential benefits of greater use of screening, though additional research on these predictive factors may be necessary as well.

These data on the success of twice-daily, 5 and 10 mg doses of tofacitinib may help inform clinicians in their practice as well as the health community in general.

These findings on both remission and low disease activity suggest that some individuals in routine clinical practice may see benefits after extending treatment with etanercept past 12 weeks.

These data were found to be consistent with the findings in the main study, the contents of which suggested the treatments’ interchangeability.

These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.

This analysis of current testing patterns in the US suggests a need for future studies to explore the rationale used to determine such testing decisions.

In this discussion, Soung discusses the VISIBLE study results on guselkumab and its design for individuals of diverse skin tones.

This study contributes to existing climate change data by exploring climatic hazards and their relationship with atopic dermatitis, in addition to highlighting research gaps and future predictions.

These data were announced by Johnson & Johnson this week and show several encouraging findings regarding guselkumab’s use among patients of different skin types.

In this interview, Del Rosso spoke on takeaways from his conference talk ‘What's New in the Medicine Chest? Acne, Rosacea, Actinic Keratoses, Psoriasis, Urticaria and Other Common Dermatoses.’

During this segment of his interview, Eingun James Song, MD, spoke about upcoming treatments for psoriasis and personalizing care for patients.

In this discussion with E. James Song, MD, several unique clinical pearls for those in dermatology were described and had been drawn from Song’s Winter Clinical presentation.

These data indicate a significant ability of this treatment to address patients’ psoriatic symptoms in a comprehensive manner, despite varying characteristics and demographics.

These data on ixekizumab in real-world settings shed light on drug survival information for both those with psoriasis and those with psoriatic arthritis.

These new data highlight the importance of larger trials to evaluate the persistence of this treatment’s efficacy and safety seen here.

This new data may help to indicate a potential common immunological mechanism, allowing for greater assessment of the effects of therapeutic agents and treatment combinations.

The Dermatology Month in Review for dermatology features 2 interviews, findings from recent long-term data, and a discussion of the FDA’s approval of secukinumab for HS.

In this retrospective review of medical charts, trends in systemic treatment use among psoriasis patients in Japan pointed to several notable findings.